Impact of combined training with different exercise intensities on inflammatory and lipid markers in type 2 diabetes: a secondary analysis from a 1-year randomized controlled trial.
Adult
Aged
Biomarkers
/ blood
Cholesterol
/ blood
Cholesterol, LDL
/ blood
Diabetes Mellitus, Type 2
/ blood
Female
High-Intensity Interval Training
Humans
Inflammation Mediators
/ blood
Interleukin-6
/ blood
Lipids
/ blood
Male
Middle Aged
Portugal
Resistance Training
Time Factors
Treatment Outcome
Exercise
High-intensity interval training
Moderate continuous training
Resistance training
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
07 10 2020
07 10 2020
Historique:
received:
22
06
2020
accepted:
23
09
2020
entrez:
8
10
2020
pubmed:
9
10
2020
medline:
18
5
2021
Statut:
epublish
Résumé
Exercise is a well-accepted strategy to improve lipid and inflammatory profile in individuals with type 2 diabetes (T2DM). However, the exercise intensity having the most benefits on lipids and inflammatory markers in patients with T2DM remains unclear. We aimed to analyse the impact of a 1-year combined high-intensity interval training (HIIT) with resistance training (RT), and a moderate continuous training (MCT) with RT on inflammatory and lipid profile in individuals with T2DM. Individuals with T2DM (n = 80, aged 59 years) performed a 1-year randomized controlled trial and were randomized into three groups (control, n = 27; HIIT with RT, n = 25; MCT with RT, n = 28). Exercise sessions were supervised with a frequency of 3 days per week. Inflammatory and lipid profiles were measured at baseline and at 1-year follow-up. Changes in inflammatory and lipid markers were assessed using generalized estimating equations. After adjusting for sex, age and baseline moderate-to-vigorous physical activity (MVPA), we observed a time-by-group interaction for Interleukin-6 (IL-6) in both the MCT with RT (β = - 0.70, p = 0.034) and HIIT with RT (β = - 0.62, p = 0.049) groups, whereas, only the HIIT with RT group improved total cholesterol (β = - 0.03, p = 0.045) and LDL-C (β = - 0.03, p = 0.034), when compared to control. No effect was observed for C-reactive protein (CRP), cortisol, tumour necrosis factor-α (TNF-α), soluble form of the haptoglobin-hemoglobin receptor CD163 (sCD163), triglycerides and HDL-C in both groups (p > 0.05). Favorable adaptations on IL-6 were observed in both the HIIT and MCT combined with RT groups following a long-term 1-year exercise intervention in individuals with T2DM. However, only the HIIT with RT prevented further derangement of total cholesterol and LDL-C, when compared to the control group. Therefore, in order to encourage exercise participation and improve inflammatory profile, either exercise protocols may be prescribed, however, HIIT with RT may have further benefits on the lipid profile. Trial registration Clinicaltrials.gov ID: NCT03144505.
Sections du résumé
BACKGROUND
Exercise is a well-accepted strategy to improve lipid and inflammatory profile in individuals with type 2 diabetes (T2DM). However, the exercise intensity having the most benefits on lipids and inflammatory markers in patients with T2DM remains unclear. We aimed to analyse the impact of a 1-year combined high-intensity interval training (HIIT) with resistance training (RT), and a moderate continuous training (MCT) with RT on inflammatory and lipid profile in individuals with T2DM.
METHODS
Individuals with T2DM (n = 80, aged 59 years) performed a 1-year randomized controlled trial and were randomized into three groups (control, n = 27; HIIT with RT, n = 25; MCT with RT, n = 28). Exercise sessions were supervised with a frequency of 3 days per week. Inflammatory and lipid profiles were measured at baseline and at 1-year follow-up. Changes in inflammatory and lipid markers were assessed using generalized estimating equations.
RESULTS
After adjusting for sex, age and baseline moderate-to-vigorous physical activity (MVPA), we observed a time-by-group interaction for Interleukin-6 (IL-6) in both the MCT with RT (β = - 0.70, p = 0.034) and HIIT with RT (β = - 0.62, p = 0.049) groups, whereas, only the HIIT with RT group improved total cholesterol (β = - 0.03, p = 0.045) and LDL-C (β = - 0.03, p = 0.034), when compared to control. No effect was observed for C-reactive protein (CRP), cortisol, tumour necrosis factor-α (TNF-α), soluble form of the haptoglobin-hemoglobin receptor CD163 (sCD163), triglycerides and HDL-C in both groups (p > 0.05).
CONCLUSIONS
Favorable adaptations on IL-6 were observed in both the HIIT and MCT combined with RT groups following a long-term 1-year exercise intervention in individuals with T2DM. However, only the HIIT with RT prevented further derangement of total cholesterol and LDL-C, when compared to the control group. Therefore, in order to encourage exercise participation and improve inflammatory profile, either exercise protocols may be prescribed, however, HIIT with RT may have further benefits on the lipid profile. Trial registration Clinicaltrials.gov ID: NCT03144505.
Identifiants
pubmed: 33028418
doi: 10.1186/s12933-020-01136-y
pii: 10.1186/s12933-020-01136-y
pmc: PMC7539392
doi:
Substances chimiques
Biomarkers
0
Cholesterol, LDL
0
IL6 protein, human
0
Inflammation Mediators
0
Interleukin-6
0
Lipids
0
Cholesterol
97C5T2UQ7J
Banques de données
ClinicalTrials.gov
['NCT03144505']
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
169Références
Scand J Clin Lab Invest. 2017 Nov;77(7):498-504
pubmed: 28715286
Nature. 2006 Dec 14;444(7121):860-7
pubmed: 17167474
Diabetes Res Clin Pract. 2018 Mar;137:149-159
pubmed: 29329778
FASEB J. 2002 Sep;16(11):1335-47
pubmed: 12205025
Ann Med Exp Biol Fenn. 1957;35(3):307-15
pubmed: 13470504
Physiol Behav. 2020 Mar 1;215:112786
pubmed: 31863856
Physiol Res. 2010;59(1):79-88
pubmed: 19249917
Diabetes Res Clin Pract. 2013 Feb;99(2):120-9
pubmed: 23183390
JAMA. 2001 Sep 12;286(10):1218-27
pubmed: 11559268
Am J Physiol Endocrinol Metab. 2001 May;280(5):E745-51
pubmed: 11287357
J Exerc Rehabil. 2016 Dec 31;12(6):575-580
pubmed: 28119880
N Engl J Med. 2018 Aug 16;379(7):633-644
pubmed: 30110583
Clin Chem. 2011 Feb;57(2):291-7
pubmed: 21106861
J Appl Physiol (1985). 2012 Apr;112(8):1353-60
pubmed: 22267387
Novartis Found Symp. 2007;286:86-94; discussion 94-8, 162-3, 196-203
pubmed: 18269176
Med Sci Sports Exerc. 2008 Jan;40(1):181-8
pubmed: 18091006
Diabetes Care. 2020 Jan;43(Suppl 1):S7-S13
pubmed: 31862744
Nutr Metab Cardiovasc Dis. 2006 Dec;16(8):543-9
pubmed: 17126770
Scand J Med Sci Sports. 2014 Apr;24(2):e69-76
pubmed: 24102912
Cardiovasc Diabetol. 2019 Mar 18;18(1):34
pubmed: 30885194
J Sports Sci. 2020 May;38(10):1150-1160
pubmed: 32228122
Obesity (Silver Spring). 2013 Dec;21(12):2437-43
pubmed: 23512476
Cardiovasc Diabetol. 2019 Aug 14;18(1):104
pubmed: 31412869
Diabetes Metab. 2016 Dec;42(6):433-441
pubmed: 27567125
Neth J Med. 2013 May;71(4):174-87
pubmed: 23723111
Vascul Pharmacol. 2018 Feb;101:9-20
pubmed: 29203287
Arch Physiol Biochem. 2015;121(4):129-38
pubmed: 26469542
Diabetes Obes Metab. 2019 Mar;21(3):550-559
pubmed: 30284352
Nutr Metab Cardiovasc Dis. 2010 Oct;20(8):608-17
pubmed: 19695853
Diabetes Care. 1997 Apr;20(4):537-44
pubmed: 9096977
Cardiovasc Diabetol. 2019 Oct 1;18(1):127
pubmed: 31575375
Horm Metab Res. 2007 Oct;39(10):707-9
pubmed: 17952830
Am J Physiol Regul Integr Comp Physiol. 2017 Apr 1;312(4):R529-R538
pubmed: 28122717
Diabetes Care. 2017 Jan;40(Suppl 1):S4-S5
pubmed: 27979887
J Physiol. 2010 Sep 15;588(Pt 18):3341-2
pubmed: 20843832
Diabetes Metab. 2017 Jun;43(3):195-210
pubmed: 28162956
J Appl Physiol (1985). 2005 Apr;98(4):1154-62
pubmed: 15772055
Metabolism. 2004 Jul;53(7):899-903
pubmed: 15254884
Prev Med Rep. 2015 Apr 28;2:314-8
pubmed: 26844086
Can J Diabetes. 2017 Oct;41(5):536-547
pubmed: 28366674
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
J Exerc Sci Fit. 2020 Jan;18(1):7-13
pubmed: 31641362
J Sci Med Sport. 2017 Oct;20(10):893-898
pubmed: 28392340
Antioxid Redox Signal. 2013 Jun 10;18(17):2352-63
pubmed: 22900885
Nat Rev Immunol. 2011 Aug 05;11(9):607-15
pubmed: 21818123
Sports Med. 2014 Feb;44(2):211-21
pubmed: 24174305